Clinical Trials Browser

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT04644289 2025-10-03

WoO

Phase 2 Recruiting

60 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

NCT06121401 2025-09-17

IOLANTHE

Phase 4 Active not recruiting

190 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

NCT05932862 2025-09-05

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Phase 1 Recruiting

429 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Phase 2 Completed

298 enrolled 18 charts

BreastGastrointestinalGenitourinaryGynecologic

Ovarian

NCT01874353 2025-08-03

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Phase 3 Active not recruiting

327 enrolled 21 charts 1 FDA

Gynecologic

Ovarian Neoplasms

NCT07069335 2025-07-16

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

Phase 1 Recruiting

24 enrolled

Gynecologic

Ovarian Neoplasms

NCT03534453 2025-07-10

L-MOCA

Phase 3 Completed

229 enrolled

Gynecologic

Ovarian Neoplasms

NCT05320757 2025-06-11

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

Phase EARLY_PHASE1 Completed

20 enrolled

Gynecologic

Endometrial Neoplasms

Clinical Trials

ENDOLA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

RAINBO

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

KEYLYNK-001

OVATION-3

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

MEDIOLA

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

ROSY-O

Study of INCB123667 in Subjects With Advanced Solid Tumors

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

BOUQUET

PROOV

QLS5132 Combination Therapy in Advanced Solid Tumors

MONO-OLA1

DOVACC

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

ATARI

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

FAB

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

RAINBO-RED

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

DUO-E

SOLO-1

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

WoO

IOLANTHE

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

L-MOCA

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients